Be The Match BioTherapies® and Atara Biotherapeutics Announce Multi-Year Partnership Extension
January 06 2022 - 10:00AM
Business Wire
Relationship Will Leverage Be The Match
BioTherapies’ Expertise and Expansive Donor Registry to Provide
Healthy Donor Cells in Support of Atara’s Allogeneic T-cell
Platform
Be The Match BioTherapies and Atara Biotherapeutics, Inc.
(Nasdaq: ATRA), today announced an extension of their collaboration
to provide high-quality healthy donor cells for Atara’s
off-the-shelf T-cell immunotherapy platform for patients with
cancer and autoimmune diseases.
This multi-year partnership leverages the capabilities of Be The
Match BioTherapies to source healthy donor cells from the Be The
Match Registry® with over 22 million genetically diverse human
leukocyte antigen (HLA) immune profiles.
“Atara and Be The Match BioTherapies share an aspiration to
serve every patient, and this partnership will allow us to deliver
treatments to the patient populations that our organization was
founded to help,” said Chris McClain, Senior Vice President, Sales
and Business Development at Be The Match BioTherapies. “We are
proud to provide a consistent supply of high-quality, compliant,
and consented HLA-specific starting material to support Atara’s
tabelecleucel (tab-cel®) program, including the ongoing Phase 3
ALLELE study, and its other pipeline candidates.”
Since 2016, Be The Match BioTherapies has been a strategic
supplier to Atara by providing the cellular starting material,
peripheral blood mononuclear cells, from healthy donors with
targeted HLA haplotypes for further manufacture and
cryopreservation as inventory ready to be delivered to patients in
need in just a few days. Cutting-edge bioinformatic insights into
HLA genetics have supported Atara’s clinical programs by ensuring
that for each product, an inventory of different manufactured lots
is available for partial matching to patient HLA profiles to
support efficacy and safety. Be The Match BioTherapies’ regulatory
expertise ensures the collection of donor cells that meet FDA and
varying international regulations, broadening the potential use of
the therapies.
“With our recent EU regulatory marketing authorization
application submission for tabelecleucel, the first-ever
off-the-shelf allogeneic T-cell therapy to be reviewed by any
regulatory agency in the world, we are one step closer to bringing
this potentially transformative treatment to patients,” said Matt
Yedwabnick, Vice President, Global Supply Chain at Atara. "Our
ability to deliver investigational medicines, including tab-cel, is
reliant on sourcing high-quality healthy donor cells. Be The Match
BioTherapies’ capabilities have been instrumental in identifying
and supplying the starting materials to produce our multiple
allogeneic T-cell and CAR-T immunotherapies in development.”
About Be The Match BioTherapies
Be The Match BioTherapies is the only cell and gene therapy
solutions provider with customizable services to support the
end-to-end cell therapy supply chain. Backed by the
industry-leading experience of the National Marrow Donor
Program®/Be The Match®, and a research partnership with the CIBMTR®
(Center for International Blood and Marrow Transplant Research®),
the organization designs solutions that advance the development of
cell and gene therapies across the globe.
Be The Match BioTherapies is dedicated to accelerating patient
access to life-saving cell and gene therapies by providing
high-quality cellular source material from the Be The Match
Registry®, the world’s most diverse registry of more than 22
million potential blood stem cell donors. Through established
relationships with apheresis, marrow collection, and transplant
centers worldwide, the organization develops, onboards, trains, and
manages expansive collection networks to advance cell therapies. Be
The Match BioTherapies uses a proven infrastructure consisting of
regulatory compliance and managed logistics experts and cell
therapy supply chain case managers to transport and deliver
regulatory-compliant life-saving therapies across the globe
successfully. Through the CIBMTR, Be The Match BioTherapies extends
services beyond the cell therapy supply chain to include long-term
follow-up tracking for the first two FDA-approved CAR-T
therapies.
For more information, visit www.BeTheMatchBioTherapies.com or
follow Be The Match BioTherapies on LinkedIn or Twitter.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell
immunotherapy leveraging its novel allogeneic EBV T-cell platform
to develop transformative therapies for patients with serious
diseases including solid tumors, hematologic cancers and autoimmune
disease. With our lead program in Phase 3 clinical development,
Atara is the most advanced allogeneic T-cell immunotherapy company
and intends to rapidly deliver off-the-shelf treatments to patients
with high unmet medical need. Our platform leverages the unique
biology of EBV T cells and has the capability to treat a wide range
of EBV-associated diseases, or other serious diseases through
incorporation of engineered CARs (chimeric antigen receptors) or
TCRs (T-cell receptors). Atara is applying this one platform, which
does not require TCR or HLA gene editing, to create a robust
pipeline including: tab-cel® in Phase 3 development for
Epstein-Barr virus-driven post-transplant lymphoproliferative
disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell
immunotherapy targeting EBV antigens as a potential treatment for
multiple sclerosis; and multiple next-generation chimeric antigen
receptor T-cell (CAR-T) immunotherapies for both solid tumors and
hematologic malignancies. Improving patients’ lives is our mission
and we will never stop working to bring transformative therapies to
those in need. Atara is headquartered in South San Francisco and
our leading-edge research, development and manufacturing facility
is based in Thousand Oaks, California. For additional information
about the company, please visit atarabio.com and follow us on
Twitter and LinkedIn.
Atara Forward-Looking Statements
This press release contains or may imply “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934. For
example, forward-looking statements include statements regarding
tab-cel®: the timing of, and Atara’s plans for, and potential
decision by, the EMA regarding the MAA submission for EBV+ patients
with PTLD, Atara’s ability to successfully advance the development
of its programs, the potential benefits to Atara as a result of the
collaboration with Be The Match BioTherapies, and Be the Match
BioTherapies’ ability to supply donor cells to Atara, including the
characteristics thereof. Because such statements deal with future
events and are based on Atara’s current expectations, they are
subject to various risks and uncertainties and actual results,
performance or achievements of Atara could differ materially from
those described in or implied by the statements in this press
release. These forward-looking statements are subject to risks and
uncertainties, including, without limitation, risks and
uncertainties associated with the costly and time-consuming
pharmaceutical product development process and the uncertainty of
clinical success; the COVID-19 pandemic, which may significantly
impact (i) our business, research, clinical development plans and
operations, including our operations in South San Francisco and
Southern California and at our clinical trial sites, as well as the
business or operations of our third-party manufacturer, contract
research organizations or other third parties with whom we conduct
business, (ii) our ability to access capital, and (iii) the value
of our common stock; the sufficiency of Atara’s cash resources and
need for additional capital; and other risks and uncertainties
affecting Atara’s and its development programs, including those
discussed in Atara’s filings with the Securities and Exchange
Commission (SEC), including in the “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” sections of the Company’s most recently filed periodic
reports on Form 10-K and Form 10-Q and subsequent filings and in
the documents incorporated by reference therein. Except as
otherwise required by law, Atara disclaims any intention or
obligation to update or revise any forward-looking statements,
which speak only as of the date hereof, whether as a result of new
information, future events or circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220106005195/en/
Be The Match BioTherapies: Bonnie Quintanilla (877)
887-7611 bonnie@clarityqst.com
Atara Biotherapeutics: Alex Chapman (805) 456-4772
achapman@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From May 2024 to Jun 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Jun 2023 to Jun 2024